A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors is a paper indexed in PICO Portal from OpenAlex.
How many citations does A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors have?
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors has 236 citations in the OpenAlex counts PICO Portal stores.
When was A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors published?
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors has 2017 year in the PICO Portal index.
What is the open-access status of A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors?
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors has closed oa status in the PICO Portal index.
What is the DOI of A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors?
The DOI for A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors is on the source record.
What is the PMID of A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors?
The PMID for A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors is on the source record.
What is the OpenAlex record for A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors?
The OpenAlex for A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors is on the source record.